Radiotherapy in adrenocortical carcinoma
Open Access
- 28 April 2009
- Vol. 115 (13), 2816-2823
- https://doi.org/10.1002/cncr.24331
Abstract
Adrenocortical carcinoma (ACC) is a rare malignancy, and patients with ACC have a poor prognosis. Even after radical surgery, up to 85% of patients develop recurrent disease. Systemic treatment options still have limited efficacy. Because the role of radiotherapy is not defined well and because ACC often is considered radioresistant, the authors reviewed the available data on radiotherapy for ACC. Original articles and reviews were identified using a PubMed search strategy that included the period up to July 2008. Ten articles were identified that covered radiotherapy in a total of 129 patients with ACC (64 patients received postoperative irradiation, and 65 patients received palliative therapy for advanced disease). In addition, 26 patients were identified in the German ACC Registry who received palliative radiotherapy. Furthermore, patterns of failure after adjuvant radiotherapy were investigated, and the authors provided recommendations for patient selection, treatment planning, and treatment protocols. In an adjuvant setting, postoperative radiotherapy was able to prevent local recurrence in the majority of patients. In those with advanced disease, a response to radiotherapy was observed in 57% of patients who received palliative radiotherapy. Therefore, the authors concluded that radiotherapy may play an important role in the care of patients with ACC. Until better evidence is available, the authors recommended the following approach: Adjuvant radiotherapy to the tumor bed should be considered in patients at high risk for local recurrence (eg, incomplete/R1 resection); a total dose of >40 grays (Gy) with single fractions of 1.8 Gy to 2 Gy should be administered (including a boost volume to reach from 50 Gy to 60 Gy in individual patients); and radiotherapy in a palliative setting may be used for symptomatic metastases to bone, brain, or vena cava obstruction. With state‐of‐the‐art technology, acute and long‐term toxicities mostly were mild to moderate. However, the authors concluded that prospective investigations would be required to fully define the therapeutic potential of this important treatment option. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 36 references indexed in Scilit:
- Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinomaCancer, 2009
- Adjuvant Mitotane Treatment for Adrenocortical CarcinomaThe New England Journal of Medicine, 2007
- Adrenocortical cancer: pathophysiology and clinical managementEndocrine-Related Cancer, 2007
- Prognostic Parameters of Metastatic Adrenocortical CarcinomaJournal of Clinical Endocrinology & Metabolism, 2007
- Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive PatientsJournal of Clinical Endocrinology & Metabolism, 2006
- Adrenocortical Carcinoma: Clinical UpdateJournal of Clinical Endocrinology & Metabolism, 2006
- Adrenocortical Carcinoma - Improving Patient Care by Establishing New StructuresExperimental and Clinical Endocrinology & Diabetes, 2006
- Management of adrenocortical carcinomaClinical Endocrinology, 2003
- Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular CharacterizationJournal of Clinical Oncology, 2002
- Adrenocortical carcinomas: surgical trends and results of a 253‐patient series from the French Association of Endocrine Surgeons study groupWorld Journal of Surgery, 2001